The therapeutic options for the indolent non-Hodgkin's lymphomas have evolved significantly over the years. However, at present, allogeneic haematopoietic stem cell transplantation (HSCT), despite its significant transplant associated complications, is still the only option which may be delivered with curative potential. The debut of reduced-intensity conditioning regimens has extended the applicability of allogeneic transplants to groups of patients ineligible for conventional myeloablative allografts. However, there are still substantial hurdles to overcome, namely that of relapse, graft-versus-host disease and infection. Whilst follow-up is still relatively limited for a disease group with a median survival of up to 10 years, early results are extremely encouraging and further studies are warranted.